Didanosine
A nucleoside reverse transcriptase inhibitor (NRTI) used as part of combination antiretroviral therapy for HIV infection by blocking the viral enzyme reverse transcriptase needed to make copies of the virus. It must be taken on an empty stomach for adequate absorption. Serious risks include pancreatitis and peripheral neuropathy, and it should not be combined with certain other antivirals.
Molecular Weight
236.2300 g/mol
LogP
-1.20
TPSA
88.70 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Incorporated into viral DNA by reverse transcriptase as a nucleoside analog, causing chain termination and inhibition of viral replication.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Incorporated into viral DNA by reverse transcriptase as a nucleoside analog, causing chain termination and inhibition of viral replication.
2D Structure
Cite this structure
Embed this structure
SMILES
O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1
InChI
InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1
Molecular Formula
C10H12N4O3
HBD / HBA
2 / 5
Rotatable Bonds
2
Heavy Atoms
17
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
A nucleoside reverse transcriptase inhibitor (NRTI) used as part of combination antiretroviral therapy for HIV infection by blocking the viral enzyme reverse transcriptase needed to make copies of the virus. It must be taken on an empty stomach for adequate absorption. Serious risks include pancreatitis and peripheral neuropathy, and it should not be combined with certain other antivirals.
Incorporated into viral DNA by reverse transcriptase as a nucleoside analog, causing chain termination and inhibition of viral replication.
Yes, Didanosine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1460. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 135398739. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="didanosine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/didanosine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/didanosine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/didanosine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="didanosine"></drugfyi-drug>